Levaquin Patent Upheld In Mylan Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan's ANDA infringes on valid patent, West Virginia district court finds. Patent protection runs until at least December 2010. J&J still faces litigation on the antibiotic from four other generic companies, but no trial date has been set.
You may also be interested in...
J&J Ditropan XL Patent Invalidated In Mylan Suit
Mylan win evens score before W.Va. District Court judge who had previously ruled J&J's Levaquin patents were valid and infringed.
J&J Ditropan XL Patent Invalidated In Mylan Suit
Mylan win evens score before W.Va. District Court judge who had previously ruled J&J's Levaquin patents were valid and infringed.
Mylan Dismisses “Authorized” Generic Antitrust Claims In W.Va. Lawsuit
Company instead is pressing on with antitrust claims filed in a March 2004 lawsuit in San Francisco state court stemming from Procter & Gamble and Watson’s “authorized” generic agreement for Macrobid. The West Virginia litigation would have been duplicative of the California claims, Mylan says.